导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.98% | 2119/4700 |
| 近一周 | -1.13% | 1685/5371 |
| 近一月 | -2.93% | 1992/5328 |
| 近一季 | -5.03% | 1915/5140 |
| 近半年 | -5.21% | 2937/4839 |
| 近一年 | 6.93% | 1513/4338 |
| 近两年 | 57.71% | 1279/2925 |
| 近三年 | 36.47% | 847/2229 |
| 成立以来 | 78.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.34% 1571/4961 |
7.58% 2688/5312 |
- - |
- - |
| 2025 | 28.68% 1463/4813 |
1.37% 1640/3635 |
2.34% 1634/4076 |
21.56% 1767/4524 |
2.03% 1106/4813 |
| 2024 | 10.55% 1402/3463 |
4.05% 484/2808 |
-4.99% 1609/3014 |
14.42% 1977/3129 |
-2.27% 2024/3463 |
| 2023 | -1.44% 512/2656 |
8.11% 497/2280 |
-2.22% 569/2385 |
-2.35% 669/2515 |
-4.51% 1068/2655 |
| 2022 | -15.25% 414/2207 |
-12.88% 663/1919 |
4.96% 954/2016 |
-8.98% 235/2113 |
1.82% 1125/2208 |
| 2021 | 15.62% 302/1822 |
-1.35% 473/1255 |
10.00% 501/1330 |
7.54% 183/1466 |
-0.92% 1285/1822 |
| 2020 | 20.69% 708/1250 |
-6.52% 492/1028 |
16.83% 409/1067 |
7.46% 781/1164 |
2.84% 963/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富安达中证500指数增强A VS. 长安沪深300非周期A(740101) |